Brugada综合征基质消融长期结局:BRAVO多中心注册研究
BRAVO国际多中心注册研究纳入159例伴自发性室颤的高危Brugada综合征患者,评估心外膜基质消融的长期疗效。单次消融后81%患者无室颤复发,重复消融后升至96%,5年无室颤生存率95%,无心律失常或心源性死亡。
要点
- 高危Brugada综合征患者心外膜基质消融安全且高效预防室颤复发。
- 单次消融后81%无复发,重复消融后96%无复发,5年无室颤生存率95%。
- 消融后1型Brugada心电图正常化与无室颤结局独立相关。
核心结论
- 心外膜基质消融可安全有效预防高危Brugada综合征患者的室颤复发。
- 消融后1型Brugada心电图正常化是与无室颤结局相关的唯一多变量分析变量。
研究设计与样本
- 多中心国际注册研究BRAVO,纳入159例伴自发性室颤的Brugada综合征患者,中位年龄42岁,156例男性。
- 43例(27%)合并早期复极模式;除5例外均植入ICD(心脏骤停125例,晕厥34例)。
- 140例(88%)消融前因自发性室颤经历多次ICD电击。
- 所有患者接受经皮心外膜基质消融联合电解剖标测,8例接受开胸消融。
主要发现
- 所有患者室颤/Brugada基质位于右心室流出道心外膜面,45例(29%)同时存在右心室下壁心外膜致心律失常基质,3例存在左心室后壁心外膜基质。
- 单次消融后128/159例(81%)无室颤复发,重复消融后增至153例(96%),平均消融1.2±0.5次(中位1次),末次消融后平均随访48±29个月。
- 室颤负荷及电击频率从消融前每月1.1±2.1次显著降至末次消融后每月0.003±0.14次(P<0.0001)。
- 末次消融后5年以上Kaplan-Meier无室颤生存率为95%。
- 多变量分析显示消融后伴或不伴钠通道阻滞下1型Brugada心电图正常化与无室颤结局相关(风险比0.078,95%CI 0.008-0.753,P=0.0274)。
临床怎么用
- 对于反复室颤的高危Brugada综合征患者,心外膜基质消融可显著减少室颤复发和ICD电击。
- 消融后1型Brugada心电图正常化可能提示治疗成功,可作为随访评估指标。
- 消融可作为选择性患者ICD植入的替代治疗,但需前瞻性研究确定适用人群。
局限性
- 为注册研究,非随机对照,无法直接比较消融与ICD的疗效。
- 需前瞻性研究确定消融能否作为选择性Brugada综合征患者ICD植入的替代治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment options for high-risk Brugada syndrome (BrS) with recurrent ventricular fibrillation (VF) are limited. Catheter ablation is increasingly performed but a large study with long-term outcome data is lacking. We report the results of the multicenter, international BRAVO (Brugada Ablation of VF Substrate Ongoing Registry) for treatment of high-risk symptomatic BrS. METHODS: We enrolled 159 patients (median age 42 years; 156 male) with BrS and spontaneous VF in BRAVO; 43 (27%) of them had BrS and early repolarization pattern. All but 5 had an implantable cardioverter-defibrillator for cardiac arrest (n=125) or syncope (n=34). A total of 140 (88%) had experienced numerous implantable cardioverter-defibrillator shocks for spontaneous VF before ablation. All patients underwent a percutaneous epicardial substrate ablation with electroanatomical mapping except for 8 who underwent open-thoracotomy ablation. RESULTS: In all patients, VF/BrS substrates were recorded in the epicardial surface of the right ventricular outflow tract; 45 (29%) patients also had an arrhythmic substrate in the inferior right ventricular epicardium and 3 in the posterior left ventricular epicardium. After a single ablation procedure, 128 of 159 (81%) patients remained free of VF recurrence; this number increased to 153 (96%) after a repeated procedure (mean 1.2±0.5 procedures; median=1), with a mean follow-up period of 48±29 months from the last ablation. VF burden and frequency of shocks decreased significantly from 1.1±2.1 per month before ablation to 0.003±0.14 per month after the last ablation (P<0.0001). The Kaplan-Meier VF-free survival beyond 5 years after the last ablation was 95%. The only variable associated with a VF-free outcome in multivariable analysis was normalization of the type 1 Brugada ECG, both with and without sodium-channel blockade, after the ablation (hazard ratio, 0.078 [95% CI, 0.008 to 0.753]; P=0.0274). There were no arrhythmic or cardiac deaths. Complications included hemopericardium in 4 (2.5%) patients. CONCLUSIONS: Ablation treatment is safe and highly effective in preventing VF recurrence in high-risk BrS. Prospective studies are needed to determine whether it can be an alternative treatment to implantable cardioverter-defibrillator implantation for selected patients with BrS. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT04420078.
引用
- Nademanee K, Chung FP, Sacher F, et al. Long-Term Outcomes of Brugada Substrate Ablation: A Report from BRAVO (Brugada Ablation of VF Substrate Ongoing Multicenter Registry). Circulation. 2023. PMID: 36960730. doi:10.1161/CIRCULATIONAHA.122.063367
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。